Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, Result: Overall, the top 10 most common NNRTI-RAMs found in this study were V90I, followed by A98G, K101E, K103N, V108I, Y181C, M184I, Y188L, G190A and H221Y (Fig 1; listed according to the most frequently detected mutation to the least).
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
PMID: 27124362
2016
Journal of acquired immune deficiency syndromes (1999)
Introduction: However, in clinical trials individuals on an ETR containing regimen who experienced virological failure were infected with viruses that had a combination of RT mutations including V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, and G190A/S.
Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
PMID: 27231099
2016
Journal of the International AIDS Society
Table: A98G
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
PMID: 27327263
2016
Journal of acquired immune deficiency syndromes (1999)
Result: Mutations conferring low to intermediate NNRTI resistance included K101E in 7 of 26 (27%), A98G 5 of 26 (19%), L100V 4 of 26 (15%), V108I in 1 of 26 (3%) and F227L in 1 of 26 (3%) of patients.
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Abstract: A relatively nonpolymorphic accessory mutation A98G-12.0% was also common.
Table: A98G
Viral Genetic Diversity and Polymorphisms in a Cohort of HIV-1-Infected Patients Eligible for Initiation of Antiretroviral Therapy in Abuja, Nigeria.
PMID: 25582324
2015
AIDS research and human retroviruses
Result: Five specimens had A98G, K101EK, V108IV, K103N, E138A, and G190A occurring alone or in combination with each other, which could cause intermediate and/or high-level resistance to delavirdine (DLV), efavirenz (EFV), etravirine (ETR), and nevirapine (NVP).
Result: We also detected NRTI selected mutations M41L, E44D, T69ANS, V75M, and V118I, and NNRTI mutations V90I, A98G, K101EQ, PMID: 25630709
2015
Global health action
Table: A98G
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
Result: Nevirapine and efavirenz resistance were predicted in about 1% and 0.5% of virus samples without NNRTI SDRMs as a result of several minimally polymorphic (e.g., A98G, V108I, and V179D) and rare nonpolymorphic (e.g., E138K, G190Q, F227C, and K238T) NNRTI-resistance mutations.
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
HIV mutation literature information.
PMID: 
2016
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT